DK3744835T3 - Dna modificerende fusionsproteiner og metoder til anvendelse deraf - Google Patents
Dna modificerende fusionsproteiner og metoder til anvendelse deraf Download PDFInfo
- Publication number
- DK3744835T3 DK3744835T3 DK20183740.8T DK20183740T DK3744835T3 DK 3744835 T3 DK3744835 T3 DK 3744835T3 DK 20183740 T DK20183740 T DK 20183740T DK 3744835 T3 DK3744835 T3 DK 3744835T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- fusion proteins
- dna modifying
- modifying fusion
- dna
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261652711P | 2012-05-29 | 2012-05-29 | |
US13/838,520 US9890364B2 (en) | 2012-05-29 | 2013-03-15 | TAL-Tet1 fusion proteins and methods of use thereof |
EP13797024.0A EP2879693B1 (en) | 2012-05-29 | 2013-05-29 | Dna modifying fusion proteins and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3744835T3 true DK3744835T3 (da) | 2024-05-06 |
DK3744835T5 DK3744835T5 (da) | 2024-08-26 |
Family
ID=49670524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK20183740.8T DK3744835T5 (da) | 2012-05-29 | 2013-05-29 | Dna modificerende fusionsproteiner og metoder til anvendelse deraf |
Country Status (5)
Country | Link |
---|---|
US (3) | US9890364B2 (da) |
EP (4) | EP4368249A3 (da) |
DK (1) | DK3744835T5 (da) |
PT (1) | PT3744835T (da) |
WO (1) | WO2013181228A1 (da) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013012674A1 (en) | 2011-07-15 | 2013-01-24 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US10801017B2 (en) * | 2011-11-30 | 2020-10-13 | The Broad Institute, Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
US20150267176A1 (en) | 2012-10-12 | 2015-09-24 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
WO2014124284A1 (en) | 2013-02-07 | 2014-08-14 | The General Hospital Corporation | Tale transcriptional activators |
KR102307280B1 (ko) | 2013-06-05 | 2021-10-01 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
EP3114227B1 (en) | 2014-03-05 | 2021-07-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
CA2948728A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11242525B2 (en) | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
WO2015191911A2 (en) * | 2014-06-12 | 2015-12-17 | Clontech Laboratories, Inc. | Protein enriched microvesicles and methods of making and using the same |
EP3247792B1 (en) | 2015-01-22 | 2021-04-14 | University of Massachusetts | Cancer immunotherapy |
EP3256487A4 (en) | 2015-02-09 | 2018-07-18 | Duke University | Compositions and methods for epigenome editing |
CA2982966C (en) | 2015-04-24 | 2024-02-20 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
WO2017066796A2 (en) * | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
WO2017066712A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
WO2017189542A1 (en) * | 2016-04-26 | 2017-11-02 | University Of Georgia Research Foundation, Inc. | Plants having reduced methylation of cytosine nucleotides and methods of use |
BR112019001887A2 (pt) | 2016-08-02 | 2019-07-09 | Editas Medicine Inc | composições e métodos para o tratamento de doença associada a cep290 |
US11780895B2 (en) | 2016-09-13 | 2023-10-10 | The Jackson Laboratory | Targeted DNA demethylation and methylation |
KR102662249B1 (ko) | 2016-10-14 | 2024-05-03 | 더 제너럴 하스피탈 코포레이션 | 후성적으로 조절되는 부위-특이적 뉴클레아제 |
EP3532638A4 (en) | 2016-10-31 | 2020-07-29 | University of Massachusetts | TARGETING MICROARN-101-3 P IN CARCINOTHERAPY |
WO2018140362A1 (en) * | 2017-01-26 | 2018-08-02 | The Regents Of The University Of California | Targeted gene demethylation in plants |
WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
WO2018209158A2 (en) | 2017-05-10 | 2018-11-15 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
US11814623B2 (en) | 2018-01-30 | 2023-11-14 | University Of Massachusetts | Methods of treating a wound using epigenetic regulation |
WO2019178426A1 (en) | 2018-03-14 | 2019-09-19 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
CN111700034B (zh) * | 2020-05-22 | 2021-12-14 | 中国人民解放军空军军医大学 | 一种基于中枢神经系统髓鞘功能改变的精神分裂症动物模型的构建方法和应用 |
WO2024073043A1 (en) * | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Methods of using cpg binding proteins in mapping modified cytosine nucleotides |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US6900306B2 (en) | 2001-08-01 | 2005-05-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of CoREST expression |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1993019202A2 (en) | 1992-03-10 | 1993-09-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Exchangeable template reaction |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
WO1994026877A1 (en) | 1993-05-17 | 1994-11-24 | The Regents Of The University Of California | Ribozyme gene therapy for hiv infection and aids |
DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
USRE45721E1 (en) | 1994-08-20 | 2015-10-06 | Gendaq, Ltd. | Relating to binding proteins for recognition of DNA |
GB9618544D0 (en) | 1996-09-05 | 1996-10-16 | Brax Genomics Ltd | Characterising DNA |
DE19812103A1 (de) | 1998-03-19 | 1999-09-23 | Bernauer Annette | Verfahren zur Synthese von Nucleinsäuremolekülen |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US8137906B2 (en) | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
DE19925862A1 (de) | 1999-06-07 | 2000-12-14 | Diavir Gmbh | Verfahren zur Synthese von DNA-Fragmenten |
US20020164575A1 (en) | 1999-09-14 | 2002-11-07 | Sangamo Biosciences, Inc., A Delaware Corporation | Gene identification |
CA2394850C (en) | 1999-12-06 | 2012-02-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
WO2001053480A1 (en) | 2000-01-24 | 2001-07-26 | Sangamo Biosciences, Inc. | Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules |
EP1276865B1 (en) | 2000-04-28 | 2014-05-21 | Sangamo BioSciences, Inc. | Methods for binding an exogenous molecule to cellular chromatin |
AU2001255870B2 (en) | 2000-04-28 | 2006-07-13 | Sangamo Biosciences, Inc. | Databases of regulatory sequences; methods of making and using same |
DE60126483T2 (de) | 2000-04-28 | 2007-12-06 | Sangamo BioSciences, Inc., Richmond | Gezielte Modifikation der Chromatinstruktur |
AU2001257331A1 (en) | 2000-04-28 | 2001-11-12 | Sangamo Biosciences, Inc. | Methods for designing exogenous regulatory molecules |
US7029847B2 (en) | 2000-05-16 | 2006-04-18 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
US6492117B1 (en) | 2000-07-12 | 2002-12-10 | Gendaq Limited | Zinc finger polypeptides capable of binding DNA quadruplexes |
EP1303608A2 (en) * | 2000-07-21 | 2003-04-23 | Syngenta Participations AG | Zinc finger domain recognition code and uses thereof |
JP2002262870A (ja) | 2000-11-09 | 2002-09-17 | Nara Institute Of Science & Technology | 固相において二本鎖dna分子を順次連結する方法およびその装置 |
US7947469B2 (en) | 2001-01-22 | 2011-05-24 | Gendaq, Ltd. | Modulation of HIV infection |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
WO2004099366A2 (en) | 2002-10-23 | 2004-11-18 | The General Hospital Corporation | Context sensitive parallel optimization of zinc finger dna binding domains |
US7741086B2 (en) | 2004-12-16 | 2010-06-22 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 |
CA2622615A1 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
GB0607063D0 (en) | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
AU2007267887B2 (en) | 2006-05-25 | 2013-05-30 | Sangamo Therapeutics, Inc. | Variant Foki Cleavage Half-Domains |
EP2235050A1 (en) | 2007-09-28 | 2010-10-06 | Two Blades Foundation | Bs3 resistance gene and methods of use |
JP2011523353A (ja) | 2008-04-28 | 2011-08-11 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 細胞透過のための過剰に荷電されたタンパク質 |
JP5746016B2 (ja) | 2008-04-30 | 2015-07-08 | サンバイオ,インコーポレイティド | Dnaメチル化における改変を伴う神経再生細胞連邦政府の援助に関する申告適用なし |
US9115386B2 (en) | 2008-09-26 | 2015-08-25 | Children's Medical Center Corporation | Selective oxidation of 5-methylcytosine by TET-family proteins |
US9133467B2 (en) | 2008-11-10 | 2015-09-15 | Two Blades Foundation | Pathogen-inducible promoters and their use in enhancing the disease resistance of plants |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
EP2424877A4 (en) | 2009-04-28 | 2013-01-02 | Harvard College | SUPERCHARGED PROTEINS FOR CELL PENETRATION |
WO2011017293A2 (en) | 2009-08-03 | 2011-02-10 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
US20110041195A1 (en) | 2009-08-11 | 2011-02-17 | Sangamo Biosciences, Inc. | Organisms homozygous for targeted modification |
US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
EP2534173B1 (en) | 2010-02-08 | 2019-09-11 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
EP2571512B1 (en) | 2010-05-17 | 2017-08-23 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CN103608027B (zh) | 2011-04-05 | 2016-01-20 | 赛莱蒂克斯公司 | 用于生成致密tale-核酸酶的方法及其用途 |
WO2013012674A1 (en) | 2011-07-15 | 2013-01-24 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US20140309145A1 (en) | 2011-07-29 | 2014-10-16 | Cellectis Sa | High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules |
HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
US20150267176A1 (en) | 2012-10-12 | 2015-09-24 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
WO2014124284A1 (en) | 2013-02-07 | 2014-08-14 | The General Hospital Corporation | Tale transcriptional activators |
CN112301024A (zh) | 2013-03-15 | 2021-02-02 | 通用医疗公司 | 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性 |
-
2013
- 2013-03-15 US US13/838,520 patent/US9890364B2/en active Active
- 2013-05-29 EP EP24153284.5A patent/EP4368249A3/en active Pending
- 2013-05-29 WO PCT/US2013/043075 patent/WO2013181228A1/en active Application Filing
- 2013-05-29 PT PT201837408T patent/PT3744835T/pt unknown
- 2013-05-29 EP EP20184257.2A patent/EP3747999B1/en active Active
- 2013-05-29 EP EP20183740.8A patent/EP3744835B1/en active Active
- 2013-05-29 EP EP13797024.0A patent/EP2879693B1/en not_active Withdrawn - After Issue
- 2013-05-29 DK DK20183740.8T patent/DK3744835T5/da active
-
2018
- 2018-02-12 US US15/894,004 patent/US10894950B2/en active Active
-
2021
- 2021-01-14 US US17/149,458 patent/US20210155907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4368249A3 (en) | 2024-07-24 |
EP2879693A1 (en) | 2015-06-10 |
EP4368249A2 (en) | 2024-05-15 |
PT3744835T (pt) | 2024-05-31 |
EP3747999B1 (en) | 2021-09-15 |
EP3747999A1 (en) | 2020-12-09 |
EP2879693B1 (en) | 2020-07-08 |
US9890364B2 (en) | 2018-02-13 |
US20180187168A1 (en) | 2018-07-05 |
EP2879693A4 (en) | 2016-04-13 |
WO2013181228A1 (en) | 2013-12-05 |
EP3744835B1 (en) | 2024-01-31 |
DK3744835T5 (da) | 2024-08-26 |
US20130323220A1 (en) | 2013-12-05 |
US10894950B2 (en) | 2021-01-19 |
US20210155907A1 (en) | 2021-05-27 |
EP3744835A1 (en) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3744835T3 (da) | Dna modificerende fusionsproteiner og metoder til anvendelse deraf | |
DK3489254T3 (da) | Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf | |
DK3321287T3 (da) | Fusionsproteiner og kombinationsvacciner | |
CL2014003605A1 (es) | Proteínas de fusión de interleuquina-10 y usos de las mismas | |
DK3058092T3 (da) | Fremgangsmåder og præparater til fremstilling af nukleinsyrebiblioteker | |
HK1213481A1 (zh) | 抗體構建體及其使用方法 | |
DK3578659T3 (da) | Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression | |
DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
DK2925782T3 (da) | Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
DK2852680T3 (da) | Fremgangsmåder og processer til ikke-invasiv evaluering af genetiske variationer | |
EP2877854A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
EP2928924A4 (en) | HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE | |
DK2812443T3 (da) | Cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
DK2859017T3 (da) | Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf | |
DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
CO7020851A2 (es) | Proteínas y péptidos modificados | |
DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
DK2912174T3 (da) | Fremgangsmåde og materialer til isolering af nukleinsyrematerialer | |
DK3604339T3 (da) | Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme | |
EP2968551A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
DK3434775T3 (da) | Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf | |
DK2812356T3 (da) | CDIM-bindende proteiner og anvendelser deraf | |
DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
DK3173102T3 (da) | FGFR-FC-fusionsprotein og anvendelse deraf |